copper sulfate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4282 7758-99-8

Description:

MoleculeDescription

Synonyms:

  • cupric sulfate
  • copper sulfate
  • copper sulfate pentahydrate
  • cupric sulfate pentahydrate
  • cupric sulfate anhydrous
A sulfate salt of copper. It is a potent emetic and is used as an antidote for poisoning by phosphorus. It also can be used to prevent the growth of algae.
  • Molecular weight: 159.60
  • Formula: CuO4S
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
May 5, 1987 FDA ABRAXIS PHARM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Contraindicated product administered 124.15 11.68 4 40251 320135 90268057
Product use in unapproved indication 115.31 11.68 9 40246 336227 90251965
Product dose omission issue 113.33 11.68 335 39920 291352 90296840
Systemic lupus erythematosus 110.43 11.68 15 40240 361881 90226311
Diarrhoea 107.32 11.68 748 39507 938442 89649750
Glossodynia 103.93 11.68 11 40244 321768 90266424
Maternal exposure during pregnancy 102.86 11.68 18 40237 360045 90228147
Pericarditis 102.56 11.68 4 40251 270147 90318045
Off label use 100.28 11.68 213 40042 1102039 89486153
Treatment failure 96.61 11.68 11 40244 303917 90284275
Infusion related reaction 92.11 11.68 35 40220 416745 90171447
Wound 89.07 11.68 14 40241 302966 90285226
Product use issue 86.91 11.68 20 40235 329899 90258293
Fall 86.75 11.68 433 39822 481377 90106815
Drug intolerance 85.77 11.68 46 40209 447545 90140647
Helicobacter infection 83.97 11.68 4 40251 226846 90361346
Unevaluable event 78.77 11.68 109 40146 54739 90533453
Device expulsion 75.50 11.68 92 40163 40794 90547398
Folliculitis 74.37 11.68 4 40251 204349 90383843
Fatigue 73.40 11.68 808 39447 1153215 89434977
Lower respiratory tract infection 62.50 11.68 17 40238 250642 90337550
Hepatic enzyme increased 62.17 11.68 42 40213 360694 90227498
Full blood count decreased 60.08 11.68 70 40185 29619 90558573
Arthropathy 58.74 11.68 46 40209 366196 90221996
Type 2 diabetes mellitus 58.35 11.68 10 40245 203234 90384958
Deep vein thrombosis 58.32 11.68 127 40128 91493 90496699
Neuropathy peripheral 57.62 11.68 162 40093 136808 90451384
Intentional product use issue 57.39 11.68 13 40242 216879 90371313
Muscle spasms 56.80 11.68 242 40013 251641 90336551
Feeling abnormal 55.52 11.68 182 40073 167053 90421139
Device dislocation 55.16 11.68 69 40186 31413 90556779
Liver injury 54.61 11.68 6 40249 170561 90417631
Nausea 53.81 11.68 739 39516 1109577 89478615
Therapeutic product effect decreased 52.43 11.68 29 40226 277542 90310650
Irritable bowel syndrome 51.84 11.68 14 40241 207434 90380758
Therapy cessation 51.81 11.68 72 40183 36289 90551903
Dizziness 49.12 11.68 437 39818 588847 89999345
General physical health deterioration 48.17 11.68 52 40203 355063 90233129
C-reactive protein increased 47.73 11.68 11 40244 181378 90406814
Haemoglobin decreased 47.40 11.68 169 40086 161787 90426405
Drug hypersensitivity 46.79 11.68 84 40171 463525 90124667
Drug ineffective 46.58 11.68 393 39862 1383905 89204287
Toxicity to various agents 45.08 11.68 37 40218 287809 90300383
Therapeutic product effect incomplete 44.97 11.68 15 40240 193881 90394311
Constipation 42.81 11.68 241 40014 280154 90308038
Plasma cell myeloma 41.37 11.68 69 40186 40759 90547433
Fibromyalgia 41.25 11.68 20 40235 206249 90381943
Blister 40.90 11.68 32 40223 254966 90333226
Asthenia 40.50 11.68 388 39867 533363 90054829
Dehydration 40.14 11.68 182 40073 194265 90393927
Back pain 39.76 11.68 259 39996 316916 90271276
Ill-defined disorder 38.40 11.68 17 40238 184874 90403318
Flatulence 38.08 11.68 67 40188 41300 90546892
Impaired healing 38.05 11.68 29 40226 234170 90354022
Urinary tract infection 37.35 11.68 248 40007 305384 90282808
Psoriasis 37.26 11.68 147 40108 147607 90440585
Pneumonia 35.51 11.68 436 39819 637623 89950569
Headache 35.28 11.68 558 39697 862188 89726004
Discomfort 35.20 11.68 42 40213 274293 90313899
Pulmonary embolism 34.48 11.68 132 40123 130688 90457504
Joint swelling 34.30 11.68 112 40143 503188 90085004
Joint range of motion decreased 34.17 11.68 9 40246 135634 90452558
Prescribed overdose 32.37 11.68 3 40252 97622 90490570
Bursitis 30.85 11.68 10 40245 131644 90456548
Intentional overdose 30.80 11.68 3 40252 93831 90494361
Hot flush 30.75 11.68 76 40179 59412 90528780
Injection site pain 29.67 11.68 154 40101 173545 90414647
Injection site erythema 28.98 11.68 103 40152 98399 90489793
Wheezing 27.90 11.68 39 40216 238041 90350151
Injection site haemorrhage 27.55 11.68 47 40208 28271 90559921
Pelvic pain 27.45 11.68 34 40221 15323 90572869
Asthma 27.07 11.68 41 40214 242119 90346073
Exposure during pregnancy 27.01 11.68 40 40215 238370 90349822
Influenza like illness 26.97 11.68 88 40167 80523 90507669
Obesity 26.57 11.68 7 40248 105500 90482692
Dyspnoea 26.50 11.68 543 39712 880412 89707780
Tremor 26.29 11.68 136 40119 153037 90435155
Wound infection 25.07 11.68 8 40247 106394 90481798
Hip fracture 24.73 11.68 49 40206 33028 90555164
Blood potassium decreased 24.69 11.68 61 40194 47666 90540526
Atrial fibrillation 24.59 11.68 121 40134 133490 90454702
White blood cell count decreased 24.40 11.68 142 40113 166967 90421225
Peripheral venous disease 24.36 11.68 4 40251 83917 90504275
Laboratory test abnormal 24.36 11.68 56 40199 41798 90546394
Rheumatoid arthritis 23.79 11.68 82 40173 362532 90225660
COVID-19 23.68 11.68 24 40231 168819 90419373
Sleep disorder 23.64 11.68 32 40223 197998 90390194
Grip strength decreased 23.59 11.68 6 40249 92570 90495622
Hypersensitivity 23.44 11.68 113 40142 454564 90133628
Alopecia 22.74 11.68 128 40127 494943 90093249
Hypervolaemia 22.67 11.68 47 40208 32710 90555482
Nasal congestion 22.66 11.68 85 40170 83329 90504863
Eye swelling 22.53 11.68 44 40211 29342 90558850
Chills 22.52 11.68 117 40138 131864 90456328
Live birth 22.46 11.68 4 40251 79103 90509089
Balance disorder 22.41 11.68 94 40161 96986 90491206
Cardiac failure congestive 22.34 11.68 95 40160 98599 90489593
Skin discolouration 22.25 11.68 56 40199 44259 90543933
Gastrointestinal disorder 22.03 11.68 51 40204 256636 90331556
Vaginal haemorrhage 21.80 11.68 45 40210 31226 90556966
Epilepsy 21.59 11.68 5 40250 82201 90505991
Blood cholesterol increased 21.57 11.68 37 40218 207975 90380217
Pulmonary arterial hypertension 21.05 11.68 40 40215 26147 90562045
Thrombosis 21.04 11.68 76 40179 73175 90515017
Hypoxia 19.85 11.68 74 40181 72325 90515867
Mobility decreased 19.81 11.68 52 40203 250682 90337510
Pulmonary hypertension 19.56 11.68 52 40203 42471 90545721
Fluid retention 19.33 11.68 84 40171 88007 90500185
Multiple sclerosis relapse 19.24 11.68 59 40196 52246 90535946
Platelet count decreased 19.10 11.68 115 40140 136854 90451338
Dysgeusia 19.06 11.68 59 40196 52501 90535691
Overdose 18.31 11.68 26 40229 157683 90430509
Vision blurred 18.28 11.68 97 40158 110196 90477996
Dyspnoea exertional 18.27 11.68 72 40183 72216 90515976
Condition aggravated 18.17 11.68 173 40082 595372 89992820
Product complaint 18.14 11.68 26 40229 13474 90574718
Lung disorder 18.11 11.68 24 40231 149859 90438333
Red blood cell sedimentation rate increased 18.10 11.68 7 40248 82588 90505604
Pulmonary fibrosis 17.85 11.68 13 40242 107490 90480702
Autoimmune disorder 17.68 11.68 6 40249 76738 90511454
Flushing 17.63 11.68 82 40173 88409 90499783
Adverse event 17.27 11.68 16 40239 117402 90470790
Dry skin 17.10 11.68 81 40174 87992 90500200
Infection 16.95 11.68 93 40162 362001 90226191
Pleural effusion 16.89 11.68 96 40159 111895 90476297
Myalgia 16.71 11.68 134 40121 174991 90413201
Hypertension 16.59 11.68 127 40128 457405 90130787
Inflammation 16.55 11.68 34 40221 178558 90409634
Tooth disorder 16.36 11.68 40 40215 31050 90557142
Swelling 16.31 11.68 114 40141 418944 90169248
International normalised ratio increased 16.14 11.68 52 40203 47264 90540928
Body height decreased 16.04 11.68 23 40232 11926 90576266
Bone pain 15.88 11.68 62 40193 61921 90526271
Abdominal discomfort 15.70 11.68 136 40119 477192 90111000
Injection site mass 15.65 11.68 32 40223 22058 90566134
Gallbladder disorder 15.61 11.68 30 40225 19773 90568419
Cellulitis 15.60 11.68 81 40174 91256 90496936
Suicide attempt 15.54 11.68 7 40248 75392 90512800
Stomatitis 15.50 11.68 66 40189 274632 90313560
Administration site swelling 15.10 11.68 9 40246 1490 90586702
Oedema peripheral 15.05 11.68 178 40077 257737 90330455
Hospice care 15.01 11.68 20 40235 9684 90578508
Illness 14.84 11.68 9 40246 81960 90506232
Depression 14.80 11.68 201 40054 300400 90287792
Injection site bruising 14.79 11.68 54 40201 52253 90535939
Anaemia 14.64 11.68 229 40026 352573 90235619
Red blood cell count decreased 14.09 11.68 49 40206 46302 90541890
Plasma cell myeloma recurrent 14.03 11.68 13 40242 4215 90583977
Pollakiuria 13.83 11.68 39 40216 32966 90555226
Intestinal dilatation 13.80 11.68 10 40245 2300 90585892
Swelling face 13.79 11.68 72 40183 81280 90506912
Lethargy 13.69 11.68 60 40195 63079 90525113
Heavy menstrual bleeding 13.68 11.68 29 40226 20501 90567691
Hypophagia 13.65 11.68 41 40214 35896 90552296
Cardiac pacemaker insertion 13.57 11.68 13 40242 4394 90583798
Drug interaction 13.49 11.68 70 40185 276383 90311809
Multiple allergies 13.26 11.68 24 40231 15122 90573070
Restless legs syndrome 13.00 11.68 30 40225 22440 90565752
Pulmonary oedema 12.71 11.68 58 40197 62022 90526170
Abdominal pain 12.53 11.68 246 40009 395475 90192717
Haematocrit decreased 12.52 11.68 44 40211 41788 90546404
Drug-induced liver injury 12.48 11.68 13 40242 90305 90497887
Complication associated with device 12.41 11.68 27 40228 19422 90568770
Night sweats 12.37 11.68 24 40231 128742 90459450
Weight decreased 12.30 11.68 237 40018 379673 90208519
Pain in jaw 12.29 11.68 48 40207 47937 90540255
Pain in extremity 12.28 11.68 274 39981 450255 90137937
Intentional product misuse 12.26 11.68 13 40242 89591 90498601
Ageusia 12.24 11.68 24 40231 16052 90572140
Cough 12.23 11.68 231 40024 368731 90219461
Liver disorder 12.18 11.68 22 40233 121247 90466945
Burning sensation 12.05 11.68 58 40197 63394 90524798
Injection site reaction 12.01 11.68 76 40179 92004 90496188
Bronchitis 11.96 11.68 112 40143 152815 90435377
Multiple sclerosis 11.76 11.68 33 40222 27807 90560385
Anxiety 11.70 11.68 198 40057 309574 90278618
Laryngeal pain 11.68 11.68 12 40243 4410 90583782

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 145.89 12.58 98 24838 638237 41958162
Product use in unapproved indication 87.77 12.58 5 24931 184451 42411948
Mite allergy 57.01 12.58 36 24900 5010 42591389
Fatigue 55.81 12.58 440 24496 435201 42161198
Mycotic allergy 55.52 12.58 35 24901 4856 42591543
Neuritis 54.81 12.58 38 24898 6182 42590217
Dust allergy 52.76 12.58 35 24901 5297 42591102
Pulmonary vasculitis 52.23 12.58 37 24899 6229 42590170
Plasma cell myeloma 52.03 12.58 97 24839 47481 42548918
Conjunctivitis allergic 51.82 12.58 36 24900 5875 42590524
Spirometry abnormal 51.45 12.58 34 24902 5112 42591287
Respiratory tract infection bacterial 47.70 12.58 23 24913 1886 42594513
Eosinophilic granulomatosis with polyangiitis 45.77 12.58 39 24897 8599 42587800
Neurological symptom 40.89 12.58 39 24897 9952 42586447
Normochromic normocytic anaemia 40.32 12.58 37 24899 8994 42587405
Drug interaction 39.95 12.58 59 24877 266940 42329459
Completed suicide 39.37 12.58 5 24931 96460 42499939
Full blood count decreased 39.16 12.58 54 24882 20506 42575893
Product dose omission issue 38.15 12.58 185 24751 154180 42442219
Respiratory tract infection viral 37.73 12.58 24 24912 3382 42593017
Drug ineffective 37.68 12.58 216 24720 629981 41966418
Laboratory test abnormal 37.38 12.58 56 24880 22922 42573477
Total lung capacity abnormal 36.48 12.58 26 24910 4417 42591982
Thrombosis 36.28 12.58 105 24831 68406 42527993
Diarrhoea 35.79 12.58 419 24517 460430 42135969
Respiratory symptom 35.63 12.58 38 24898 11068 42585331
Asthenia 34.39 12.58 281 24655 280512 42315887
Pulmonary alveolar haemorrhage 32.97 12.58 42 24894 14774 42581625
Fall 32.75 12.58 242 24694 234278 42362121
Toxicity to various agents 32.01 12.58 53 24883 229083 42367316
White blood cell count decreased 31.47 12.58 138 24798 110258 42486141
Arteriosclerosis coronary artery 29.64 12.58 45 24891 18632 42577767
Arteriosclerosis 29.49 12.58 44 24892 17945 42578454
Nodule 28.63 12.58 36 24900 12498 42583901
Capillaritis 27.97 12.58 17 24919 2211 42594188
Forced expiratory volume decreased 27.89 12.58 28 24908 7602 42588797
Vasculitis 27.35 12.58 43 24893 18351 42578048
Adverse drug reaction 26.57 12.58 64 24872 37370 42559029
Antineutrophil cytoplasmic antibody positive 25.81 12.58 21 24915 4344 42592055
Full blood count abnormal 25.56 12.58 55 24881 29821 42566578
General physical health deterioration 25.04 12.58 31 24905 151215 42445184
Intentional product misuse 23.42 12.58 4 24932 61896 42534503
Viral infection 22.30 12.58 44 24892 22439 42573960
Dizziness 21.23 12.58 231 24705 249023 42347376
Pneumonia 20.65 12.58 354 24582 421795 42174604
Febrile neutropenia 19.91 12.58 50 24886 185653 42410746
Platelet count decreased 19.87 12.58 144 24792 138437 42457962
Treatment failure 19.80 12.58 6 24930 62618 42533781
Psoriasis 19.75 12.58 68 24868 48536 42547863
Pulmonary fibrosis 19.34 12.58 46 24890 26635 42569764
Multiple organ dysfunction syndrome 19.30 12.58 17 24919 97018 42499381
Interstitial lung disease 19.21 12.58 11 24925 78451 42517948
Haemoptysis 19.12 12.58 65 24871 46102 42550297
Sleep disorder due to a general medical condition 18.34 12.58 35 24901 17418 42578981
Muscle spasms 17.67 12.58 98 24838 85946 42510453
Hypoxia 17.47 12.58 84 24852 69702 42526697
Regurgitation 17.44 12.58 12 24924 1928 42594471
Drug ineffective for unapproved indication 17.43 12.58 3 24933 46160 42550239
Sinusitis 17.37 12.58 64 24872 47228 42549171
Neuropathy peripheral 17.07 12.58 110 24826 101743 42494656
Overdose 16.97 12.58 22 24914 105242 42491157
Cytokine release syndrome 16.58 12.58 3 24933 44524 42551875
Influenza 16.41 12.58 76 24860 62099 42534300
Eructation 16.25 12.58 18 24918 5468 42590931
Hepatic function abnormal 16.20 12.58 5 24931 51562 42544837
Foetal exposure during pregnancy 15.95 12.58 4 24932 47307 42549092
Pulmonary embolism 15.84 12.58 122 24814 119490 42476909
Cardiac disorder 15.34 12.58 63 24873 48869 42547530
Obstructive airways disorder 15.13 12.58 40 24896 24719 42571680
Rash 14.89 12.58 236 24700 276718 42319681
Peripheral swelling 14.82 12.58 97 24839 90173 42506226
Dehydration 14.25 12.58 136 24800 141631 42454768
Influenza like illness 14.23 12.58 46 24890 31794 42564605
Anxiety 14.11 12.58 118 24818 118442 42477957
Hypothyroidism 14.02 12.58 46 24890 32038 42564361
Unevaluable event 13.95 12.58 48 24888 34240 42562159
Coma 13.85 12.58 7 24929 53547 42542852
Mental status changes 13.82 12.58 55 24881 42060 42554339
Constipation 13.60 12.58 150 24786 162141 42434258
Product use issue 13.48 12.58 15 24921 76736 42519663
Haemoglobin decreased 13.27 12.58 127 24809 132344 42464055
Small intestinal obstruction 13.00 12.58 30 24906 17031 42579368
Flatulence 12.78 12.58 38 24898 25114 42571285
Leukopenia 12.70 12.58 15 24921 74731 42521668

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 200.56 10.96 247 51676 1499938 109037438
Product use in unapproved indication 166.99 10.96 11 51912 447366 110090010
Product dose omission issue 104.96 10.96 361 51562 321421 110215955
Treatment failure 99.99 10.96 8 51915 277226 110260150
Contraindicated product administered 99.20 10.96 4 51919 248263 110289113
Fall 90.94 10.96 538 51385 602944 109934432
Completed suicide 90.26 10.96 6 51917 242375 110295001
Drug intolerance 85.49 10.96 42 51881 406470 110130906
Systemic lupus erythematosus 84.73 10.96 10 51913 254328 110283048
Device expulsion 81.63 10.96 86 51837 30805 110506571
Drug ineffective 76.87 10.96 411 51512 1520129 109017247
Product use issue 75.56 10.96 26 51897 311669 110225707
Diarrhoea 74.85 10.96 840 51083 1138665 109398711
Infusion related reaction 73.41 10.96 44 51879 381118 110156258
Plasma cell myeloma 69.53 10.96 114 51809 62822 110474554
Fatigue 68.71 10.96 871 51052 1215087 109322289
Toxicity to various agents 68.24 10.96 75 51848 480480 110056896
Duodenal ulcer perforation 67.34 10.96 4 51919 177696 110359680
Glossodynia 66.38 10.96 12 51911 221992 110315384
Helicobacter infection 66.27 10.96 5 51918 181872 110355504
Maternal exposure during pregnancy 65.80 10.96 19 51904 254864 110282512
Dizziness 63.43 10.96 551 51372 697642 109839734
Pericarditis 61.03 10.96 14 51909 219100 110318276
Pulmonary embolism 60.83 10.96 230 51693 214244 110323132
Mite allergy 59.66 10.96 36 51887 5767 110531609
Lower respiratory tract infection 59.39 10.96 20 51903 243086 110294290
Deep vein thrombosis 59.38 10.96 172 51751 139715 110397661
Asthenia 58.59 10.96 536 51387 688463 109848913
Pulmonary vasculitis 58.07 10.96 37 51886 6523 110530853
Folliculitis 57.32 10.96 6 51917 167647 110369729
General physical health deterioration 56.47 10.96 70 51853 425225 110112151
Neuritis 56.39 10.96 38 51885 7361 110530015
Mycotic allergy 56.26 10.96 35 51888 5919 110531457
Spirometry abnormal 56.25 10.96 34 51889 5463 110531913
Dust allergy 56.01 10.96 35 51888 5966 110531410
Dehydration 55.49 10.96 269 51654 279242 110258134
Conjunctivitis allergic 53.79 10.96 36 51887 6895 110530481
Therapy cessation 53.31 10.96 84 51839 44773 110492603
Haemoglobin decreased 52.73 10.96 244 51679 248483 110288893
Drug hypersensitivity 50.20 10.96 85 51838 454005 110083371
Hepatic enzyme increased 50.19 10.96 46 51877 320846 110216530
Full blood count decreased 48.06 10.96 67 51856 32032 110505344
Respiratory tract infection bacterial 47.36 10.96 23 51900 2393 110534983
Hypoxia 47.23 10.96 151 51772 129364 110408012
Dyspnoea 47.21 10.96 755 51168 1106117 109431259
Drug interaction 47.12 10.96 103 51820 500080 110037296
Irritable bowel syndrome 46.72 10.96 10 51913 164205 110373171
Eosinophilic granulomatosis with polyangiitis 46.01 10.96 39 51884 10647 110526729
Intentional product use issue 45.79 10.96 30 51893 247876 110289500
Device dislocation 45.72 10.96 65 51858 31639 110505737
C-reactive protein increased 45.05 10.96 23 51900 217896 110319480
Unevaluable event 44.73 10.96 91 51832 59136 110478240
Intentional overdose 44.64 10.96 5 51918 132496 110404880
Type 2 diabetes mellitus 44.31 10.96 14 51909 177218 110360158
Wound 42.45 10.96 29 51894 234408 110302968
Fibromyalgia 41.84 10.96 14 51909 170895 110366481
Feeling abnormal 41.83 10.96 182 51741 180529 110356847
Total lung capacity abnormal 40.94 10.96 26 51897 4557 110532819
Arthropathy 40.64 10.96 45 51878 287477 110249899
Intentional product misuse 40.12 10.96 7 51916 132897 110404479
Normochromic normocytic anaemia 39.30 10.96 39 51884 13018 110524358
Thrombosis 38.99 10.96 126 51797 108536 110428840
Neurological symptom 38.67 10.96 42 51881 15566 110521810
Joint swelling 38.63 10.96 95 51828 442750 110094626
Respiratory symptom 38.40 10.96 41 51882 14904 110522472
Pneumonia 37.68 10.96 599 51324 876115 109661261
Nausea 35.74 10.96 794 51129 1234896 109302480
Liver injury 35.65 10.96 13 51910 150400 110386976
Muscle spasms 34.94 10.96 237 51686 277920 110259456
Hypervolaemia 33.86 10.96 73 51850 49387 110487989
Ill-defined disorder 33.25 10.96 16 51907 156837 110380539
Pulmonary alveolar haemorrhage 33.10 10.96 44 51879 20106 110517270
Respiratory tract infection viral 32.86 10.96 25 51898 5853 110531523
Fluid retention 31.73 10.96 107 51816 94200 110443176
Mental status changes 31.71 10.96 93 51830 76029 110461347
Arteriosclerosis 31.69 10.96 48 51875 24719 110512657
Therapeutic product effect decreased 31.58 10.96 41 51882 244275 110293101
Bursitis 31.18 10.96 11 51912 129907 110407469
Cardiac failure congestive 31.15 10.96 147 51776 150853 110386523
Capillaritis 30.01 10.96 17 51906 2422 110534954
Hospice care 29.92 10.96 33 51890 12440 110524936
Platelet count decreased 28.73 10.96 196 51727 230247 110307129
Blister 28.53 10.96 39 51884 227337 110310039
Overdose 28.44 10.96 41 51882 233753 110303623
Joint range of motion decreased 28.09 10.96 11 51912 121821 110415555
Flatulence 28.04 10.96 70 51853 52079 110485297
Prescribed overdose 27.81 10.96 4 51919 87577 110449799
Influenza like illness 27.73 10.96 98 51825 88314 110449062
Hip fracture 27.72 10.96 55 51868 35096 110502280
Antineutrophil cytoplasmic antibody positive 27.08 10.96 21 51902 5055 110532321
Arteriosclerosis coronary artery 27.07 10.96 45 51878 25073 110512303
Hypercholesterolaemia 26.95 10.96 5 51918 90832 110446544
Multiple sclerosis relapse 26.55 10.96 67 51856 50173 110487203
Peripheral venous disease 26.35 10.96 4 51919 84113 110453263
Haematocrit decreased 25.86 10.96 79 51844 66038 110471338
Dyspnoea exertional 25.77 10.96 107 51816 103953 110433423
Anxiety 25.56 10.96 261 51662 344817 110192559
COVID-19 25.14 10.96 48 51875 245012 110292364
White blood cell count decreased 25.06 10.96 189 51734 229201 110308175
Pelvic pain 24.95 10.96 34 51889 15908 110521468
Haemoptysis 24.93 10.96 82 51841 71272 110466104
Obesity 24.90 10.96 11 51912 113340 110424036
Epilepsy 24.89 10.96 8 51915 100201 110437175
Back pain 24.86 10.96 275 51648 370721 110166655
Full blood count abnormal 24.82 10.96 70 51853 55982 110481394
Mobility decreased 24.80 10.96 46 51877 237376 110300000
Urinary tract infection 24.75 10.96 248 51675 326034 110211342
Blood potassium decreased 24.37 10.96 68 51855 54046 110483330
Gastrointestinal disorder 24.29 10.96 48 51875 241904 110295472
Headache 24.19 10.96 563 51360 881814 109655562
Viral infection 24.15 10.96 67 51856 53072 110484304
Rheumatoid arthritis 24.03 10.96 67 51856 299546 110237830
Injection site pain 23.78 10.96 154 51769 177768 110359608
International normalised ratio increased 23.71 10.96 92 51831 86680 110450696
Injection site erythema 23.45 10.96 97 51826 94079 110443297
Illness 23.38 10.96 5 51918 82166 110455210
Pulmonary arterial hypertension 23.37 10.96 49 51874 32519 110504857
Constipation 22.97 10.96 263 51660 357523 110179853
Cytokine release syndrome 22.82 10.96 3 51920 70303 110467073
Cellulitis 22.66 10.96 118 51805 125898 110411478
Neuropathy peripheral 22.65 10.96 153 51770 179124 110358252
Small intestinal obstruction 22.57 10.96 48 51875 32165 110505211
Grip strength decreased 22.56 10.96 5 51918 80169 110457207
Pulmonary hypertension 22.55 10.96 67 51856 55153 110482223
Discomfort 22.07 10.96 42 51881 214665 110322711
Forced expiratory volume decreased 22.00 10.96 29 51894 13147 110524229
Therapeutic response decreased 21.77 10.96 9 51914 96490 110440886
Injection site haemorrhage 21.75 10.96 48 51875 32980 110504396
Impaired healing 21.54 10.96 37 51886 196680 110340696
Chills 21.36 10.96 158 51765 190422 110346954
Drug ineffective for unapproved indication 21.03 10.96 11 51912 102827 110434549
Exposure during pregnancy 20.71 10.96 29 51894 167395 110369981
Tremor 20.62 10.96 164 51759 202068 110335308
Eye swelling 20.61 10.96 47 51876 33001 110504375
Pain in extremity 20.54 10.96 332 51591 486786 110050590
Complication associated with device 20.35 10.96 35 51888 20038 110517338
Pleural effusion 20.30 10.96 148 51775 177561 110359815
Live birth 20.24 10.96 4 51919 69480 110467896
Suicide attempt 19.79 10.96 12 51911 103382 110433994
Dysgeusia 19.77 10.96 75 51848 69910 110467466
Nasal congestion 19.77 10.96 95 51828 98187 110439189
Inflammation 19.68 10.96 38 51885 193200 110344176
Coma 19.50 10.96 16 51907 117853 110419523
Flushing 19.47 10.96 99 51824 104637 110432739
Hypertension 19.39 10.96 150 51773 509934 110027442
Product complaint 19.20 10.96 28 51895 13944 110523432
Autoimmune disorder 18.59 10.96 4 51919 65479 110471897
Cardiac disorder 18.54 10.96 78 51845 76202 110461174
Vaginal haemorrhage 18.31 10.96 38 51885 25036 110512340
Oedema peripheral 18.22 10.96 235 51688 328425 110208951
Gastrointestinal haemorrhage 17.86 10.96 136 51787 165382 110371994
Drug-induced liver injury 17.84 10.96 18 51905 120049 110417327
Eructation 17.64 10.96 27 51896 14030 110523346
Hepatic function abnormal 17.60 10.96 10 51913 89285 110448091
Eosinophilia 17.59 10.96 3 51920 57933 110479443
Wound infection 17.36 10.96 12 51911 96453 110440923
Liver disorder 17.24 10.96 25 51898 142218 110395158
Stomatitis 17.13 10.96 67 51856 270175 110267201
Bronchitis 16.92 10.96 129 51794 156903 110380473
Transfusion 16.75 10.96 37 51886 25435 110511941
Nodule 16.70 10.96 43 51880 32588 110504788
Productive cough 16.55 10.96 101 51822 114204 110423172
Weight decreased 16.49 10.96 310 51613 467747 110069629
Depressed level of consciousness 16.49 10.96 17 51906 112261 110425115
Laryngeal pain 16.44 10.96 17 51906 5958 110531418
Atrial fibrillation 16.19 10.96 172 51751 229470 110307906
Bone pain 16.14 10.96 67 51856 65066 110472310
Abdominal pain 16.14 10.96 334 51589 512655 110024721
Atelectasis 15.43 10.96 45 51878 36667 110500709
Multiple organ dysfunction syndrome 15.31 10.96 30 51893 151680 110385696
Agranulocytosis 15.21 10.96 5 51918 61755 110475621
Vasculitis 15.10 10.96 44 51879 35829 110501547
Infection 14.96 10.96 104 51819 362096 110175280
Red blood cell count decreased 14.94 10.96 66 51857 65857 110471519
Heavy menstrual bleeding 14.62 10.96 27 51896 16338 110521038
Disease progression 14.59 10.96 177 51746 243857 110293519
Pain in jaw 14.58 10.96 55 51868 51122 110486254
Cholestasis 14.58 10.96 6 51917 64512 110472864
Interstitial lung disease 14.54 10.96 27 51896 139307 110398069
Alopecia 14.45 10.96 106 51817 364647 110172729
Gallbladder disorder 14.35 10.96 31 51892 20998 110516378
Blepharospasm 14.31 10.96 4 51919 54847 110482529
Cytomegalovirus infection 14.15 10.96 4 51919 54440 110482936
Myalgia 14.05 10.96 163 51760 222218 110315158
Depression 14.01 10.96 218 51705 317117 110220259
Infective pulmonary exacerbation of cystic fibrosis 14.00 10.96 25 51898 14746 110522630
Hypersensitivity 13.88 10.96 122 51801 403876 110133500
Chest pain 13.85 10.96 251 51672 376124 110161252
Drug reaction with eosinophilia and systemic symptoms 13.76 10.96 11 51912 82084 110455292
Red blood cell sedimentation rate increased 13.75 10.96 10 51913 78292 110459084
Nail disorder 13.74 10.96 5 51918 57930 110479446
Application site erythema 13.73 10.96 15 51908 5595 110531781
Hypophagia 13.73 10.96 55 51868 52571 110484805
Blood cholesterol increased 13.59 10.96 43 51880 184742 110352634
Therapeutic product effect incomplete 13.24 10.96 57 51866 223748 110313628
Hospitalisation 13.15 10.96 113 51810 142380 110394996
Drug resistance 13.14 10.96 5 51918 56369 110481007
Rotator cuff syndrome 12.91 10.96 26 51897 16768 110520608
Hepatitis 12.82 10.96 14 51909 90040 110447336
Lethargy 12.50 10.96 81 51842 93495 110443881
Psoriasis 12.39 10.96 110 51813 139883 110397493
Cardiac pacemaker insertion 12.31 10.96 15 51908 6286 110531090
Vision blurred 12.27 10.96 103 51820 128919 110408457
Blood glucose decreased 12.25 10.96 36 51887 29452 110507924
Application site pain 12.25 10.96 14 51909 5485 110531891
Hypothyroidism 12.24 10.96 67 51856 72832 110464544
Death 12.14 10.96 421 51502 698448 109838928
Application site discolouration 12.07 10.96 7 51916 1042 110536334
Hot flush 11.98 10.96 62 51861 65974 110471402
Febrile neutropenia 11.63 10.96 94 51829 316673 110220703
Regurgitation 11.60 10.96 11 51912 3474 110533902
Gait disturbance 11.48 10.96 189 51734 278019 110259357
Night sweats 11.46 10.96 29 51894 133954 110403422
Granulocytopenia 11.39 10.96 21 51902 12694 110524682
Aspartate aminotransferase increased 11.37 10.96 120 51803 159816 110377560
Anaphylactic shock 11.32 10.96 5 51918 51541 110485835
Intestinal dilatation 11.24 10.96 11 51912 3609 110533767
Swelling face 11.18 10.96 78 51845 92243 110445133
Osteoarthritis 11.11 10.96 46 51877 182577 110354799
Rib fracture 11.08 10.96 38 51885 33732 110503644
Balance disorder 11.05 10.96 93 51830 116467 110420909

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V03AB20 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Antidotes
MeSH PA D000931 Antidotes
MeSH PA D004639 Emetics
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D020011 Protective Agents
CHEBI has role CHEBI:75835 anti-anaemic agent

Related Drugs by ATC class:

V03AB Antidotes 28 drugs
4-dimethylaminophenolacetylcysteineamyl nitriteandexanet alfaatropinedimercaprolethanolflumazenilfomepizoleglutathionehydroxocobalaminidarucizumab show all 28 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypocupremia contraindication 19577007
Wilson's disease contraindication 88518009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (1ML) TRALEMENT AM REGENT N209376 July 2, 2020 RX SOLUTION INTRAVENOUS 11975022 July 1, 2041 ADULT AND PEDIATRIC PATIENTS WEIGHING AT LEAST 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED
EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (1ML) TRALEMENT AM REGENT N209376 July 2, 2020 RX SOLUTION INTRAVENOUS 12150956 July 1, 2041 ADULT AND PEDIATRIC PATIENTS WEIGHING AT LEAST 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED
EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (1ML) TRALEMENT AM REGENT N209376 July 2, 2020 RX SOLUTION INTRAVENOUS 12150957 July 1, 2041 ADULT AND PEDIATRIC PATIENTS WEIGHING AT LEAST 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED
EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (5ML) TRALEMENT AM REGENT N209376 Dec. 2, 2020 RX SOLUTION INTRAVENOUS 11975022 July 1, 2041 ADULT AND PEDIATRIC PATIENTS WEIGHING AT LEAST 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED
EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (5ML) TRALEMENT AM REGENT N209376 Dec. 2, 2020 RX SOLUTION INTRAVENOUS 12150956 July 1, 2041 ADULT AND PEDIATRIC PATIENTS WEIGHING AT LEAST 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED
EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (5ML) TRALEMENT AM REGENT N209376 Dec. 2, 2020 RX SOLUTION INTRAVENOUS 12150957 July 1, 2041 ADULT AND PEDIATRIC PATIENTS WEIGHING AT LEAST 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED
EQ 60MCG COPPER/ML;EQ 3MCG BASE/ML;EQ 6MCG SELENIUM/ML;EQ 1000MCG BASE/ML (1ML) MULTRYS AM REGENT N209376 June 30, 2021 RX SOLUTION INTRAVENOUS 11975022 July 1, 2041 NEONATAL AND PEDIATRIC PATIENTS WEIGHING LESS THAN 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED
EQ 60MCG COPPER/ML;EQ 3MCG BASE/ML;EQ 6MCG SELENIUM/ML;EQ 1000MCG BASE/ML (1ML) MULTRYS AM REGENT N209376 June 30, 2021 RX SOLUTION INTRAVENOUS 12150956 July 1, 2041 NEONATAL AND PEDIATRIC PATIENTS WEIGHING LESS THAN 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED
EQ 60MCG COPPER/ML;EQ 3MCG BASE/ML;EQ 6MCG SELENIUM/ML;EQ 1000MCG BASE/ML (1ML) MULTRYS AM REGENT N209376 June 30, 2021 RX SOLUTION INTRAVENOUS 12150957 July 1, 2041 NEONATAL AND PEDIATRIC PATIENTS WEIGHING LESS THAN 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4020097 VUID
N0000148098 NUI
D03613 KEGG_DRUG
7758-98-7 SECONDARY_CAS_RN
4017628 VANDF
4017650 VANDF
4017708 VANDF
4020097 VANDF
C0056301 UMLSCUI
CHEBI:23414 CHEBI
CHEMBL604 ChEMBL_ID
D019327 MESH_DESCRIPTOR_UI
DB06778 DRUGBANK_ID
24462 PUBCHEM_CID
1999541 RXNORM
3686 MMSL
37539 MMSL
39943 MMSL
4503 MMSL
4513 MMSL
6110 MMSL
72601 MMSL
d04204 MMSL
000855 NDDF
001946 NDDF
007446 NDDF
423960007 SNOMEDCT_US
70168001 SNOMEDCT_US
LRX7AJ16DT UNII
LRX7AJ16DT INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Multitrace-5 HUMAN PRESCRIPTION DRUG LABEL 5 0517-8510 INJECTION, SOLUTION 1.57 mg INTRAVENOUS UNAPPROVED DRUG OTHER 14 sections
Multitrace -4 Pediatric HUMAN PRESCRIPTION DRUG LABEL 4 0517-9203 INJECTION, SOLUTION, CONCENTRATE 0.40 mg INTRAVENOUS UNAPPROVED DRUG OTHER 14 sections
Multrys HUMAN PRESCRIPTION DRUG LABEL 4 0517-9302 INJECTION, SOLUTION 150 ug INTRAVENOUS NDA 19 sections
Tralement HUMAN PRESCRIPTION DRUG LABEL 4 0517-9305 INJECTION, SOLUTION 0.30 mg INTRAVENOUS NDA 22 sections
Strovite OneCaplets HUMAN PRESCRIPTION DRUG LABEL 20 0642-0207 TABLET 1.50 mg ORAL unapproved drug other 14 sections
Se-Tan PLUS HUMAN PRESCRIPTION DRUG LABEL 13 13925-118 CAPSULE, GELATIN COATED 0.80 mg ORAL unapproved drug other 18 sections
Quflora Pediatric Drops HUMAN PRESCRIPTION DRUG LABEL 13 15370-100 LIQUID 1 mg ORAL UNAPPROVED DRUG OTHER 11 sections
Quflora Pediatric Drops HUMAN PRESCRIPTION DRUG LABEL 13 15370-101 LIQUID 1 mg ORAL UNAPPROVED DRUG OTHER 11 sections
Quflora Pediatric HUMAN PRESCRIPTION DRUG LABEL 14 15370-103 TABLET, CHEWABLE 1 mg ORAL UNAPPROVED DRUG OTHER 12 sections
Quflora Pediatric HUMAN PRESCRIPTION DRUG LABEL 14 15370-104 TABLET, CHEWABLE 1 mg ORAL UNAPPROVED DRUG OTHER 12 sections
Quflora Pediatric HUMAN PRESCRIPTION DRUG LABEL 14 15370-105 TABLET, CHEWABLE 1 mg ORAL UNAPPROVED DRUG OTHER 12 sections
Centratex HUMAN PRESCRIPTION DRUG LABEL 13 23359-100 CAPSULE 0.80 mg ORAL unapproved drug other 13 sections
C-Nate DHA HUMAN PRESCRIPTION DRUG LABEL 13 23359-105 CAPSULE, GELATIN COATED 1 mg ORAL unapproved drug other 15 sections
Concept OB HUMAN PRESCRIPTION DRUG LABEL 15 52747-620 CAPSULE 800 ug ORAL unapproved drug other 13 sections
Concept DHA HUMAN PRESCRIPTION DRUG LABEL 15 52747-621 CAPSULE, LIQUID FILLED 2 mg ORAL unapproved drug other 7 sections
PureVit DualFe Plus HUMAN PRESCRIPTION DRUG LABEL 13 59088-112 CAPSULE 0.80 mg ORAL unapproved drug other 12 sections
Dexatran HUMAN PRESCRIPTION DRUG LABEL 13 59088-643 CAPSULE 0.80 mg ORAL unapproved drug other 12 sections
Viva CT Prenatal HUMAN PRESCRIPTION DRUG LABEL 12 64661-811 TABLET, CHEWABLE 1 mg ORAL UNAPPROVED DRUG OTHER 16 sections
AQUATEC ALONGLIFE HUMAN OTC DRUG LABEL 1 80224-1000 SOLUTION 0.03 mg TOPICAL OTC monograph not final 10 sections
NANO - Q1 HUMAN OTC DRUG LABEL 1 80224-2000 SOLUTION 0.03 mg TOPICAL OTC monograph not final 10 sections